Phase of Development: HTS / Hit ID
Mechanism of Action: Tau Proteostasis, Propagation and Clearance
Compound Type/Modality: Small Molecule
Advancing a Human Stem Cell-Based Platform to Support Discovery of Tauopathy Therapeutics
Stephen Haggarty, PhD
Associate Professor, Department of Neurology, Harvard Medical School Director, Chemical Neurobiology Laboratory, Center for Genomic Medicine Associate Neuroscientist, Massachusetts General Hospital Senior Associate Member, Broad Institute of MIT & Harvard Affiliate Faculty, Harvard Stem Cell Institute

For further information about this program Contact:
-
Project Lead
Drug Discovery drugdiscovery@rainwatercf.org